<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2272">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255017</url>
  </required_header>
  <id_info>
    <org_study_id>TJ20200128</org_study_id>
    <nct_id>NCT04255017</nct_id>
  </id_info>
  <brief_title>A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia</brief_title>
  <official_title>An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, there is no specific and effective antiviral therapy.In this study, an open,
      prospective/retrospective, randomized controlled cohort study was designed to compare the
      efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the
      efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of
      2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To
      provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by
      new coronavirus infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of disease remission</measure>
    <time_frame>two weeks</time_frame>
    <description>A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2&gt; 93% or PaO2/FiO2&gt;300mmHg (1mmHg=0.133Kpa);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for lung recovery</measure>
    <time_frame>two weeks</time_frame>
    <description>Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of no fever</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of respiratory symptom remission</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of lung imaging recovery</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of undetectable viral RNA</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>2019-nCoV</condition>
  <arm_group>
    <arm_group_label>Symptomatic supportive treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Symptomatic supportive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abidol hydrochloride was added on the basis of group I.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abidol hydrochloride 0.2g once,3 times a day,2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oseltamivir was added on the basis of group I.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir 75mg once,twice a day,2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir was added on the basis of group I.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lopinavir/ritonavir 500mg once,twice a day,2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abidol hydrochloride</intervention_name>
    <description>Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.</description>
    <arm_group_label>Abidol hydrochloride was added on the basis of group I.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.</description>
    <arm_group_label>Oseltamivir was added on the basis of group I.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.</description>
    <arm_group_label>Lopinavir/ritonavir was added on the basis of group I.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 2019-nCoV nucleic acid test was positive.

          2. CT of the lung conformed to the manifestation of viral pneumonia.

        Exclusion Criteria:

          1. Patients who meet any of the contraindications in the experimental drug labeling

          2. Patients who do not want to participate in this clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qing Ning, Professor</last_name>
    <phone>+8613971521450</phone>
    <email>qning@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meifang Han, Professor</last_name>
    <phone>+8613986093605</phone>
    <email>mfhan@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department and Institute of Infectious Disease</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Ning, professor</last_name>
      <email>qning@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Meifang Han, professor</last_name>
      <email>mfhan@foxmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

